Natera, Inc. is a leader in cell-free DNA (cfDNA) testing, focusing on genetic testing and diagnostics in oncology, women's health, and organ health. Founded in 2004 and based in Austin, Texas, the company utilizes advanced molecular biology techniques and proprietary bioinformatics software to deliver accurate, noninvasive genetic tests. Natera's mission is to integrate personalized genetic testing into standard healthcare practices, aiming to improve patient outcomes and extend healthy lives.

The company offers a wide range of cfDNA-based tests, including Signatera for cancer monitoring, Panorama for noninvasive prenatal screening, and Prospera for assessing kidney transplant rejection risk. Other tests include Aletra for genomic profiling, Renasight for kidney disease detection, and Empower for hereditary cancer risk assessment. Natera's technology platform boasts over 250 patents and supports its commitment to innovation and clinical validation, with extensive support for patients and healthcare providers.